Japan Science and Technology Agency

Riken Corporation

Other

Kyowa Hakko Kogyo Co., Ltd.

Japan Science and Technology Corporation

Katsuhiko Mikoshiba

Akinobu Suzuki

Teiichi Furuichi

Hideaki Ando

Akihiro Mizutani

Tsuyoshi Uchiyama

Fumio Yoshikawa

Junji Hirota

Shoichiro Ozaki

Etsuko Ebisui

Jun-ichi Goto

Akiko Terauchi

Takeshi Nakamura

Hideyuki Okano

Takayuki Maruyama

Shin-ichi Hamano

Akinori Tokunaga

Kouzo Hamada

Takeshi Nara

Muneaki Hashimoto

Hiroyuki Kabayama

Kozo Hamada

Hirohide Iwasaki

Masato Nakafuku

Tetsu Yoshida

Takao Imai

Aiko Nakamura, Legal Representative

Kyoko Nakamura, Legal Representative

Shouichirou Ozaki

Nobuyuki Nukina

A therapeutic agent for treating a-associated disease; a method of preventing infection byparasites, or killingparasites; and use thereof, the therapeutic agent and the method each using a mechanism different from a mechanism used in conventional technology. The therapeutic agent of the present invention for treating a-associated disease includes, as a medicinal component, an antisense oligonucleotide suppressing the expression of an inositol 1,4,5-trisphosphate receptor protein ofparasites.

[object Object]

The present invention includes a treating step of treating neuronal growth cone with a regulatory factor to regulate macropinocytosis caused by a repulsive axon guidance molecule. The present invention can provide a new neuronal axon elongation regulating method etc.

Method of regulating neuronal axon elongation

The present invention relates to: a ketone compound having transglutaminase-inhibiting activity, which is represented by the following Formula 1, 2, or 3: wherein Ris a substituted or unsubstituted aryl or heterocyclyl group, R, R, and Rare hydrogen atoms, n is 2, X is halogen, Rand Rindependently represent a hydrogen atom or a substituted or unsubstituted C1-C10 alkyl, aryl, or aralkyl group, wherein Rand Rare not hydrogen atoms at the same time, or Rand Rmay be taken together to form a saturated or unsaturated and substituted or unsubstituted heterocyclyl group containing a nitrogen atom (N); an inhibitor of protein crosslinking comprising the compound; and a composition for preventing or treating a protein-crosslinking causative disease, which comprises the compound or the protein crosslinking inhibitor.

Inhibitor of protein crosslinking and use of the same

The present invention provides a protein cross-linking inhibitor containing a compound represented by any of the following formulas (1)-(13), or a pharmaceutically acceptable salt thereof:R&#x2014;[&#x2014;X&#x2014;B(ZR)&#x2014;Y&#x2014;B(ZR)&#x2014;W&#x2014;]&#x2014;R,&#x2003;&#x2003;(1)R&#x2014;[&#x2014;X&#x2014;B(ZR)&#x2014;Y&#x2014;]&#x2014;R,&#x2003;&#x2003;(2)R&#x2014;[&#x2014;B(ZR)&#x2014;Y&#x2014;B(ZR)&#x2014;W&#x2014;]&#x2014;R,&#x2003;&#x2003;(3)R&#x2014;[&#x2014;X&#x2014;B(ZR)&#x2014;]&#x2014;R,&#x2003;&#x2003;(4)R&#x2014;[&#x2014;B(ZR)&#x2014;W&#x2014;]&#x2014;R,&#x2003;&#x2003;(5)R&#x2014;X&#x2014;B(ZR)-T[B(ZR)&#x2014;W&#x2014;R],&#x2003;&#x2003;(6)R&#x2014;B(OH),&#x2003;&#x2003;(7)R&#x2014;B(ZR)&#x2014;X&#x2014;B(ZR)&#x2014;R,&#x2003;&#x2003;(8)R&#x2014;B(R)&#x2014;O&#x2014;B(R)&#x2014;R,&#x2003;&#x2003;(9)R&#x2014;[&#x2014;X&#x2014;B(ZR)&#x2014;Y&#x2014;B(ZR)&#x2014;]&#x2014;R,&#x2003;&#x2003;(10)R&#x2014;[&#x2014;X&#x2014;B(ZR)&#x2014;Y&#x2014;B(ZR)&#x2014;W-Q-]&#x2014;R,&#x2003;&#x2003;(11)R&#x2014;[&#x2014;P&#x2014;X&#x2014;B(ZR)&#x2014;Y&#x2014;B(ZR)&#x2014;W&#x2014;]&#x2014;R,&#x2003;&#x2003;(12)[R&#x2014;X&#x2014;B(ZR)&#x2014;Y]B(ZR),&#x2003;&#x2003;(13)wherein each symbol is as defined in the DESCRIPTION.

Protein cross-linking inhibitor

The present invention provides a composition comprising an IPreceptor-binding protein (IRBIT), a nucleic acid that controls the expression and translation of IRBIT, or an antibody against IRBIT for controlling at least one intracellular biological function selected from the group consisting of (1) protein synthesis, (2) phosphatidylinositol metabolism, and (3) intracellular pH.

In vitro control of protein synthesis in mammalian cells by IP3 receptor-binding protein

A bisboron compound represented by the general formula (I): wherein B represents a boron atom, Y represents an oxygen or sulfur atom, Rand Rindependently represent a monocyclic aromatic group, a polycyclic aromatic group, or a heterocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulfur atoms, Rrepresents a hydrogen atom; &#x2014;(CH)&#x2014;NRR; &#x2014;CO&#x2014;(CH)&#x2014;NRR; &#x2014;COCH(NH)R; &#x2014;CHRR; &#x2014;CHCH(NH)&#x2014;R; quinolyl substituted with C1-C4 alkyl group; or C1-C4 alkyl substituted with pyridyl, piperidino or pyrrolidinyl group, and X represents a monocyclic aromatic group, a polycyclic aromatic group or a heterocyclic group, which may be the same as or different from Rand R, or a bifunctional group having a monocyclic aromatic group, polycyclic aromatic group or heterocyclic group bonded to each side of a group selected from the group consisting of a single bond, O, CH, S, SO, CHOCH, OCH, OCHCHOCH, OCHOCHCHand CHOCHCH, or a salt thereof, and a composition for controlling the intracellular calcium concentration, which comprises the compound or salt thereof as an active ingredient.

Bisboron compound

Analysis of substance capable of binding with inositol-1,4,5-triphosphate (IP) receptor (IPR), preferably with a regulation domain of IPR; analysis of the function of IPR; and establishing of a method of treatment or diagnosis for various malfunctions and diseases associated with IPR. In particular, control of the activity of intracellular Carelease. More specifically, a regulator for the activity of inositol-1,4,5-triphosphate (IP) receptor (IPR), comprised of carbonic anhydrase related protein (CARP); a control agent for intracellular calcium release, comprised of carbonic anhydrase related protein (CARP); and a method of control therewith.

Control of function of intracellular Ca ion

Analysis of substance capable of binding with inositol-1, 4,5-triphosphate (IP) receptor (IPR), preferably with a regulation domain of IPR; analysis of the function of IPR; and establishing of a method of treatment or diagnosis for various malfunctions and diseases associated with IPR. In particular, control of the activity of intracellular Carelease. More specifically, a regulator for the activity of inositol-1,4, 5-triphosphate (IP) receptor (IPR), comprised of carbonic anhydrase related protein (CARP); a control agent for intracellular calsium release, comprised of carbonic anhydrase related protein (CARP); and a method of control therewith.

An Numb protein expression inhibitor comprising, as active ingredient, Musashi protein, a polypeptide having an amino acid sequence obtained by replacement, deletion, addition or insertion of at least one amino acid in an amino acid sequence of Musashi protein, or a gene encoding said polypeptide. By the present invention, a new function of Musashi protein has been elucidated. Described specifically, Musashi protein inhibits expression of Numb protein having a neuronal differentiation regulating function and potentiates the activity of the Notch signaling system, so that Musashi protein can be used as a therapeutic for various diseases of the central nervous system.

Numb protein expression inhibitors by Musashi

An intracellular calcium concentration increase inhibitor containing as the active ingredient (1) a boron compound represented by the formula (I).  The compound represented by the formula (I) inhibits the increase of the intracellular calcium concentration, and therefore it is deemed to be useful as an agent for the prophylaxis and/or treatment of platelet aggregation, ischemic diseases in hearts and brains, immune deficiency diseases, allorgosis, bronchial asthma, hypertension, cerebrovascular spasm, various renal diseases, pancreatitis, Alzheimer's disease, etc.

Intracellular calcium concentration increase inhibitors

The present invention provides a high affinity polypeptide having a binding activity to inositol 1,4,5-trisphosphate, to a gene encoding the polypeptide, to a recombinant vector including the gene, to a transformant including the vector and to a method for producing the high affinity polypeptide having a binding activity to inositol 1,4,5-trisphosphate.

RNA-binding protein

Nucleic acids, vectors and transformed cells for making and using high affinity IP-3 binding polypeptides

A polypeptide capable of binding to inositol 1,4,5-trisphosphate, a deoxyribonucleic acid (DNA) coding for said polypeptide, a recombinant plasmid harboring said DNA or a part thereof, a microorganism and animal cells each harboring said plasmid, and a method of producing said polypeptide.

Growing community of inventors

Tokyo, Japan

Katsuhiko Mikoshiba